Bausch Health Companies Inc - Asset Resilience Ratio
Bausch Health Companies Inc (BHC) has an Asset Resilience Ratio of 4.97% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of Bausch Health Companies Inc to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how Bausch Health Companies Inc's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Bausch Health Companies Inc to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Bausch Health Companies Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Bausch Health Companies Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$1.31 Billion | 4.97% |
| Short-term Investments | CA$0.00 | 0% |
| Total Liquid Assets | CA$1.31 Billion | 4.97% |
Asset Resilience Insights
- Limited Liquidity: Bausch Health Companies Inc maintains only 4.97% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Bausch Health Companies Inc Industry Peers by Asset Resilience Ratio
Compare Bausch Health Companies Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 1.28% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Procter & Gamble Health Limited
NSE:PGHL |
Drug Manufacturers - Specialty & Generic | 33.01% |
Annual Asset Resilience Ratio for Bausch Health Companies Inc (1999–2025)
The table below shows the annual Asset Resilience Ratio data for Bausch Health Companies Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 4.97% | CA$1.31 Billion ≈ $946.91 Million |
CA$26.32 Billion ≈ $19.04 Billion |
+0.52pp |
| 2024-12-31 | 4.45% | CA$1.18 Billion ≈ $854.32 Million |
CA$26.52 Billion ≈ $19.19 Billion |
+0.99pp |
| 2023-12-31 | 3.46% | CA$947.00 Million ≈ $685.05 Million |
CA$27.35 Billion ≈ $19.78 Billion |
+1.27pp |
| 2022-12-31 | 2.20% | CA$564.00 Million ≈ $407.99 Million |
CA$25.69 Billion ≈ $18.58 Billion |
+0.20pp |
| 2021-12-31 | 1.99% | CA$582.00 Million ≈ $421.01 Million |
CA$29.20 Billion ≈ $21.12 Billion |
+0.05pp |
| 2020-12-31 | 1.94% | CA$605.00 Million ≈ $437.65 Million |
CA$31.20 Billion ≈ $22.57 Billion |
-7.64pp |
| 2019-12-31 | 9.58% | CA$3.24 Billion ≈ $2.35 Billion |
CA$33.86 Billion ≈ $24.50 Billion |
+6.95pp |
| 2018-12-31 | 2.63% | CA$721.00 Million ≈ $521.56 Million |
CA$27.45 Billion ≈ $19.85 Billion |
+0.71pp |
| 2017-12-31 | 1.92% | CA$720.00 Million ≈ $520.84 Million |
CA$37.50 Billion ≈ $27.12 Billion |
+0.67pp |
| 2016-12-31 | 1.25% | CA$543.00 Million ≈ $392.80 Million |
CA$43.53 Billion ≈ $31.49 Billion |
+1.21pp |
| 2015-12-31 | 0.03% | CA$16.00 Million ≈ $11.57 Million |
CA$48.96 Billion ≈ $35.42 Billion |
-0.13pp |
| 2014-12-31 | 0.16% | CA$43.00 Million ≈ $31.11 Million |
CA$26.35 Billion ≈ $19.06 Billion |
+0.07pp |
| 2013-12-31 | 0.09% | CA$25.20 Million ≈ $18.23 Million |
CA$27.97 Billion ≈ $20.23 Billion |
+0.07pp |
| 2012-12-31 | 0.02% | CA$4.41 Million ≈ $3.19 Million |
CA$17.95 Billion ≈ $12.99 Billion |
-0.02pp |
| 2011-12-31 | 0.05% | CA$6.34 Million ≈ $4.58 Million |
CA$13.14 Billion ≈ $9.51 Billion |
-0.01pp |
| 2010-12-31 | 0.06% | CA$6.08 Million ≈ $4.40 Million |
CA$10.80 Billion ≈ $7.81 Billion |
-0.41pp |
| 2009-12-31 | 0.46% | CA$9.57 Million ≈ $6.92 Million |
CA$2.07 Billion ≈ $1.50 Billion |
+0.40pp |
| 2008-12-31 | 0.06% | CA$997.00K ≈ $721.21K |
CA$1.62 Billion ≈ $1.17 Billion |
-0.16pp |
| 2007-12-31 | 0.22% | CA$3.90 Million ≈ $2.82 Million |
CA$1.78 Billion ≈ $1.29 Billion |
+0.20pp |
| 2005-12-31 | 0.02% | CA$511.00K ≈ $369.65K |
CA$2.19 Billion ≈ $1.58 Billion |
-0.23pp |
| 2004-12-31 | 0.25% | CA$5.02 Million ≈ $3.63 Million |
CA$2.01 Billion ≈ $1.46 Billion |
-10.13pp |
| 1999-12-31 | 10.38% | CA$65.90 Million ≈ $47.67 Million |
CA$635.10 Million ≈ $459.42 Million |
-- |
About Bausch Health Companies Inc
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmac… Read more